FindTrial
Sign In

Efficacy of Faviprevir in COVID-19 Treatment

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04351295
Enrollment
92
Registered
2020-04-17
Start date
2020-04-20
Completion date
2020-09-28
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID

Brief summary

Faviprevir in COVID-19 treatment

Detailed description

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment

Interventions

DRUGFavipiravir

Favipiravir

DRUGChloroquine

chloroquine oral tablets

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with covid 19

Exclusion criteria

* Allergy or contraindications to faviprevir

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with mortality or need for mechanical ventilation6 monthsNumber of patients with mortality or need for mechanical ventilation

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026